While genomics may be inching toward the clinic, from a business perspective, the research end-market remains the prime target for most entrepreneurs in the space, writes Art Wuster at his Sequenomics blog.

Wuster looked at 72 firms listed on the technology company database Crunchbase, all of which received at least some third-party funding, and found that 38 were companies with customers in research laboratories or in other genomic firms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

A Virtual Worm

The Online Comments

Hidden in the Data

Better Smarts

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.